Tranexamic Acid Should NOT Be Used in Dengue Fever with GI Bleeding
Do not administer tranexamic acid to patients with dengue fever and gastrointestinal bleeding. This recommendation is based on the established ineffectiveness of tranexamic acid in non-traumatic GI bleeding and the unique pathophysiology of dengue hemorrhagic complications.
Evidence Against Use in GI Bleeding
The most recent and highest-quality evidence demonstrates that tranexamic acid is ineffective for upper gastrointestinal hemorrhage. The HALT-IT study conclusively showed no benefit in GI bleeding regardless of anticoagulant status 1. The 2025 French emergency medicine guidelines explicitly state this finding with GRADE 1+ evidence 1.
While some meta-analyses suggest potential benefit in upper GI bleeding 2, 3, the most rigorous systematic review found that extended-use high-dose IV tranexamic acid does not reduce mortality (RR 0.98,95% CI 0.88-1.09) or bleeding (RR 0.92,95% CI 0.82-1.04) but significantly increases thromboembolic complications 4:
- Deep venous thrombosis: RR 2.01 (95% CI 1.08-3.72)
- Pulmonary embolism: RR 1.78 (95% CI 1.06-3.0)
- Seizures: RR 1.73 (95% CI 1.03-2.93)
Specific Concerns in Dengue
Dengue fever presents unique contraindications for tranexamic acid:
Thrombotic Risk in Dengue
Dengue hemorrhagic fever involves plasma leakage, endothelial dysfunction, and a complex coagulopathy that differs fundamentally from traumatic or surgical bleeding 5, 6. The pathophysiology includes:
- Capillary leak syndrome
- Platelet dysfunction beyond simple thrombocytopenia
- Endothelial activation predisposing to both bleeding AND thrombosis
Adding an antifibrinolytic agent to this already prothrombotic milieu significantly increases the risk of venous and arterial thromboembolism 7.
Validated Indications Exclude Dengue
Tranexamic acid has proven efficacy ONLY in specific contexts 1, 8, 9, 8:
- Trauma with hemorrhagic shock (within 3 hours of injury)
- Post-partum hemorrhage (within 3 hours of birth) 10
- Emergency cardiac surgery
- Hemophilia-related bleeding during dental procedures 11
None of these indications apply to dengue-associated GI bleeding, which represents a medical (non-traumatic) hemorrhagic condition with distinct pathophysiology.
Appropriate Management Strategy
For dengue fever with GI bleeding, focus on:
- Fluid resuscitation - Careful crystalloid administration to maintain perfusion without exacerbating plasma leakage
- Blood component therapy - Platelet transfusion if count <20,000/μL with active bleeding or <10,000/μL prophylactically; packed red blood cells for hemodynamic instability
- Endoscopic intervention - Direct hemostasis with clips and adrenaline injection for identified bleeding sources 5
- Supportive care - Monitor hematocrit, platelet count, and signs of plasma leakage (pleural effusion, ascites)
Critical Pitfall to Avoid
Do not extrapolate trauma guidelines to medical bleeding conditions. The CRASH-2 trial's success in trauma 8, 9, 8 does not translate to non-traumatic GI bleeding, as confirmed by multiple guidelines 1. The mechanism of bleeding in dengue (endothelial dysfunction, plasma leakage, consumptive coagulopathy) fundamentally differs from traumatic hemorrhage where hyperfibrinolysis predominates.
The risk-benefit ratio clearly favors avoiding tranexamic acid in dengue-associated GI bleeding, given the lack of efficacy evidence, increased thrombotic risk, and availability of effective alternative interventions.